Botulinum Toxin Use in Neurourology - PubMed (original) (raw)

Botulinum Toxin Use in Neurourology

Benoit Peyronnet et al. Rev Urol. 2018.

Abstract

The use of botulinum toxin A (BTX-A) has revolutionized the treatment of neurogenic lower urinary tract dysfunction (NLUTD) over the past three decades. Initially, it was used as a sphincteric injection for detrusor sphincter dyssynergia but now is used mostly as intradetrusor injection to treat neurogenic detrusor overactivity (NDO). Its use is supported by high-level-of-evidence studies and it has become the gold-standard treatment for patients with NDO refractory to anticholinergics. Several novelties have emerged in the use of BTX-A in neurourology over the past few years. Although onabotulinumtoxinA (BOTOX®, Allergan, Inc., Irvine, CA) remains the only BTX-A for which use is supported by large, multicenter, randomized, controlled trials (RCT), and is therefore the only one to be licensed in the United States and Europe, a second BTX-A, abobotulinumtoxinA (Dysport®, Ipsen Biopharmaceuticals, Basking Ridge, NJ), is also supported by high-level-of-evidence studies. Other innovations in the use of BTX-A in neurourology during the past few years include the BTX switch (from abobotulinumtoxinA to onabotulinumtoxinA or the opposite) as a rescue option for primary or secondary failures of intradetrusor BTX-A injection and refinements in intradetrusor injection techniques (number of injection sites, injection into the trigone). There is also a growing interest in long-term failure of BTX-A for NDO and their management, and a possible new indication for urethral sphincter injections.

Keywords: Botulinum toxin; Injection; Neurogenic detrusor overactivity; Sphincter.

PubMed Disclaimer

References

    1. Chermansky CJ, Chancellor MB. Use of botulinum toxin in urologic diseases. Urology. 2016;91:21–32. -PubMed
    1. Dressler D. Botulinum toxin drugs: brief history and outlook. J Neural Transm (Vienna). 2016;123:277–279. -PubMed
    1. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139:919–922. -PubMed
    1. Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinence with botulinum toxin A . N Engl J Med. 2000;342:665. -PubMed
    1. Moore DC, Cohn JA, Dmochowski RR. Use of botulinum toxin A in the treatment of lower urinary tract disorders: a review of the literature. Toxins (Basel). 2016;8:88. -PMC -PubMed

LinkOut - more resources